TL;DR
Scientists have discovered a novel, conserved binding site within Class B GPCRs that can be targeted by small molecule drugs. This finding opens up new avenues for developing orally active medications for a range of diseases, moving beyond current injectable peptide therapies.
What Problem Does This Paper Address?
Class B G protein-coupled receptors (GPCRs), like those for GLP-1 and PTH, are crucial drug targets for conditions such as diabetes, obesity, and osteoporosis. While injectable peptide drugs exist, there's a significant unmet need for orally available small molecule agonists. Developing these has been challenging because natural ligands are peptides that bind to large pockets, requiring interaction with both the transmembrane domain (TMD) and extracellular domain (ECD) of the receptor. Previous small molecule drugs for Class B GPCRs have been found to bind either in the peptide binding site or at an allosteric site, but a truly novel and broadly applicable binding site for small molecules remained elusive.
Methods
The researchers utilized cryo-electron microscopy (cryo-EM) to determine the high-resolution structure of the human parathyroid hormone receptor 1 (PTH1R) in complex with a small molecule agonist, PCO371, and its stimulatory G protein (Gs). This structural information was then combined with functional assays, including cAMP accumulation and β-arrestin recruitment assays, to understand the signaling properties of PCO371. They also employed site-directed mutagenesis to identify key residues involved in PCO371 binding and activation. Homology modeling was used to predict the conservation of the PCO371 binding site across other Class B GPCRs.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- A Novel Binding Site: The most striking finding is the discovery of a completely new binding site for PCO371. Unlike previously reported small molecule or peptide ligands, PCO371 binds at the interface between the PTH1R and the Gs protein, within the transmembrane domain. This is a significant departure from conventional understanding.
- Conserved Pocket: Crucially, the residues forming this PCO371 binding pocket are highly conserved across Class B GPCRs. This suggests that this pocket is a druggable target not just for PTH1R but for a broad range of Class B GPCRs.
- G Protein Bias: PCO371 acts as a G protein-biased agonist, meaning it preferentially activates G protein signaling pathways while being defective in promoting β-arrestin signaling. This bias is important for therapeutic development, as it can lead to desired effects with fewer side effects.
- Orally Active Potential: The discovery of this novel, conserved binding site within the TMD, which is accessible without necessarily engaging the ECD, is a key step towards developing orally active small molecule drugs. This bypasses the need for complex interactions typically required by peptide ligands.
Key Results
- The high-resolution cryo-EM structure revealed PCO371 binding at an unexpected site between PTH1R and Gs, distinct from all previously known GPCR ligand binding sites.
- Mutagenesis studies identified key hydrophobic residues within this pocket that are essential for PCO371's potency and specificity.
- Functional assays confirmed PCO371 as a G protein-biased agonist, showing robust cAMP production but impaired β-arrestin signaling.
- Single residue mutations in PTH2R and two-residue mutations in GLP-1R were sufficient to confer responsiveness to PCO371, highlighting the conserved nature of the binding pocket.
- Homology modeling and experimental testing showed that this PCO371-like pocket is conserved in most Class B GPCRs, with PCO371 activating several wild-type Class B GPCRs and mutated versions of others.
Limitations and Future Work
The authors acknowledge that while PCO371 shows pan-agonist activity in some wild-type Class B GPCRs, further research is needed to understand its selectivity and potential for off-target effects. The study primarily focuses on PTH1R, and while homology modeling suggests conservation, experimental validation across a wider range of Class B GPCRs is ongoing. Future work will likely focus on:
- Designing and developing more selective small molecule agonists targeting this conserved pocket for specific Class B GPCRs.
- Further exploring the therapeutic potential of PCO371 and related compounds for diseases like hypoparathyroidism and osteoporosis.
- Investigating the precise mechanisms of G protein bias and its implications for therapeutic outcomes.
- Expanding the structural and functional characterization of this binding site in other Class B GPCRs.
Summary updated